Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Chemotherapy signatures reveal the evolutionary history of post-melphalan myeloid neoplasm
    Meeting Abstract

    Diamond, B.; Ziccheddu, B.; Maclachlan, K.; Taylor, J.; Boyle, E.; Coffey, D.; Lu, S.; Bolli, N.; Bolton, K.; Park, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • BRUIN CLL-314: A phase III open-label, randomized study of pirtobrutinib (LOXO-305) versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
    Meeting Abstract

    Woyach, J. A.; Wierda, W. G.; Coombs, C. C.; Lewis, K. L.; Gribben, J. G.; Escalon, M. P.; Ceccarelli, M.; Wu, X.; Mato, A. R.
    Blood (2022)

    Fulltext@MSK | Save
  • Siremadlin in combination with venetoclax (VEN) plus azacitidine (AZA) in adult patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy: A phase Ib/II trial
    Meeting Abstract

    Daver, N.; Wei, A. H.; Stein, E.; DeAngelo, D. J.; Pathak, D.; Xu, Y.; Grzesiak, S.; Venditti, A.
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 1b study of IDH inhibition with enasidenib and MEK inhibition with cobimetinib in patients with relapsed or refractory acute myeloid leukemia who have co-occurring IDH2 and RAS signaling gene mutations
    Meeting Abstract

    Ball, B. J.; Stein, E.; Robbins, M.; Zhang, J.; Levine, R. L.; Synold, T.; Stein, A. S.; Marcucci, G.; Liu, Y.; Danilov, A. V.
    Blood (2022)

    Fulltext@MSK | Save
  • Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab
    Meeting Abstract

    Parisi, R.; Cowen, E. A.; Gu, S.; Pulitzer, M.; Geyer, M. B.; King, A. C.; Markova, A.
    Blood (2022)

    Fulltext@MSK | Save
  • Improvement in individual symptoms and total symptom score (TSS) and matching-adjusted indirect comparison (MAIC) analysis to compare TSS as a continuous endpoint in patients with myelofibrosis treated with pelabresib in combination with ruxolitinib versus janus kinase inhibitor monotherapy
    Meeting Abstract

    Mesa, R.; Kremyanskaya, M.; Patriarca, A.; Gupta, V.; Palandri, F.; Devos, T.; Harrison, C.; Rampal, R. K.; Talpaz, M.; Vannucchi, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Comparison of patients with newly diagnosed (ND) acute myeloid leukemia (AML) treated with venetoclax and hypomethylating agents vs other therapies by TP53 and IDH1/2 mutation: Results from the AML Real World Evidence (ARC) Initiative
    Meeting Abstract

    Wolach, O.; Garcia, J. S.; Desai, P.; Vachhani, P.; Zeidner, J. F.; Abedin, S.; Sweet, K.; Lai, C.; Moshe, Y.; Pollyea, D. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • An ongoing pilot study of targeted radioimmunotherapy (131-I apamistamab) conditioning prior to CD19-targeted CAR T-cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma
    Meeting Abstract

    Geyer, M. B.; Cadzin, B.; Hosszu, K.; Senechal, B.; Spross, J. A.; Mark, A.; Desai, A.; Cathcart, E. R.; Palomba, M. L.; Pandit-Taskar, N.
    Blood (2022)

    Fulltext@MSK | Save
  • Outcomes of therapies and resistance mutations following non-covalent Bruton's Tyrosine Kinase inhibitor treatment for patients with chronic lymphocytic leukemia and Richter Transformation
    Meeting Abstract

    Thompson, M. C.; Coombs, C. C.; Roeker, L. E.; Jensen, J. L.; Shah, N. N.; Luo, T.; Patel, K.; Bailey, N.; Fakhri, B.; Eyre, T. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Incidence, clinical associations, and co-mutation patterns of UBA1 mutations in MDS
    Meeting Abstract

    Sirenko, M.; Bernard, E.; Beck, D. B.; Creignou, M.; Domenico, D.; Farina, A.; Arango, J. E.; Kosmider, O.; Hasserjian, R. P.; Jadersten, M.; more...
    Blood (2022)

    Fulltext@MSK | Save